ICON Public Limited Company
ICLR
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $12.5B
$164.91
▲ +0.81%
P/E
71.39
Mkt Cap
$12.5B
52-Wk Range
$66.57–$203.91
52-Week Range
$66.57 - $203.91
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 7.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Value
Attractively priced below sector peer average
Momentum
Strong
+7.1% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ICLR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
JUL 29, 2026
Reported EPS of $2.56 vs $2.55 consensus (+0.4% surprise). Revenue of $2.1B vs $2.0B expected (+3.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
2 of 2 beats
Estimate
Actual
Q3 26
+0.4%
Q2 26
+2.9%
Revenue trend · last 2Q
—
+2%
Q1 26
Q2 26
$2.0B
$2.1B
Margins · last 2Q
Gross
18.8%
Operating
9.4%
Profit
3.5%
Wall Street consensus
7 analysts · 43% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
43%
Hold
57%
Sell
0%
Median Price Target
—
Latest: Citi · Jul 31, 2026
vs Industry
How ICLR stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.